U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C19H24N2S.C14H10O4
Molecular Weight 554.699
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0
Stereo Comments C19H24N2S

SHOW SMILES / InChI
Structure of PROFENAMINE HIBENZATE

SMILES

OC(=O)C1=C(C=CC=C1)C(=O)C2=CC=C(O)C=C2.CCN(CC)C(C)CN3C4=CC=CC=C4SC5=CC=CC=C35

InChI

InChIKey=MJRQYMOUGYDNHE-UHFFFAOYSA-N
InChI=1S/C19H24N2S.C14H10O4/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21;15-10-7-5-9(6-8-10)13(16)11-3-1-2-4-12(11)14(17)18/h6-13,15H,4-5,14H2,1-3H3;1-8,15H,(H,17,18)

HIDE SMILES / InChI

Molecular Formula C14H10O4
Molecular Weight 242.2268
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H24N2S
Molecular Weight 312.472
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Ethopropazine is an anticholinergic drug. Ethopropazine is an inhibitor of butyrylcholinesterase and non-selective muscarinic acetylcholine receptor antagonist. Ethopropazine has been used for the treatment of parkinsonism and drug-induced extrapyramidal reactions. Also It used for the symptomatic treatment of hepatolenticular degeneration and congenital athetosis.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
88.0 nM [Kd]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PARSIDOL
Primary
PARSIDOL
Primary
PARSIDOL
Primary
PARSIDOL

Funbound

ValueDoseCo-administeredAnalytePopulation
7%
PROFENAMINE unknown
Homo sapiens

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Tox targets

Sourcing

PubMed

Sample Use Guides

In Vivo Use Guide
ETHOPROPAZINE HYDROCHLORIDE TABLETS USP Usual adult and adolescent dose Parkinsonism and Drug-induced extrapyramidal reactions Oral, 50 mg one or two times a day, the dosage being increased as needed and tolerated. In severe cases, the dose may be increased gradually to a total of 500 to 600 mg a day.
Route of Administration: Oral
In Vitro Use Guide
The racemate and the enantiomers of ethopropazine were tested in vitro for their cellular toxicity using lung fibroblast cells. Each enantiomer was shown to be cytotoxic at concentrations greater than 10 uM.
Substance Class Chemical
Record UNII
K9CM14VTI2
Record Status Validated (UNII)
Record Version